Market-ready oral solution for sensory dysfunction in peripheral neuropathy

Overview

cGP-Pro is an innovative oral solution designed to address sensory dysfunction in peripheral neuropathy. Unlike traditional analgesics that primarily alleviate symptoms, cGP-Pro works by enhancing underlying nerve function. It delivers cyclic glycine-proline (cGP), a naturally occurring peptide that supports IGF-1 function, promoting microvascular remodeling and nerve repair pathways. This approach not only improves nerve function but also potentially reduces neuropathic discomfort over time. In a 6-month open-label study involving adults with type 2 diabetes and diabetic peripheral neuropathy, cGP-Pro demonstrated improvement in foot sensation and clinical neuropathy scores, proving its effectiveness in modifying nerve function.

Technical specifications

• Format: Available as standardized bulk powder or finished capsules
• Mechanism of Action: Targets underlying nerve pathology by delivering physiological doses of cGP to support IGF-1 function and microvascular integrity
• Bioavailability: Orally bioavailable in humans, identical to the endogenous peptide
• Clinical Evidence: Supported by human data showing proof of concept in diabetic peripheral neuropathy
• Study Protocols: Ready for randomized, double-blind, placebo-controlled trials in various populations

Technology readiness level

The technology is at TRL 7, indicating a system prototype demonstration in an operational environment. cGP-Pro is prepared for market entry with existing human data and ready-to-activate clinical trials, subject to regulatory and compliance requirements.